Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
VWcyfjsd912eUGp5
